Mirabegron extended-release tablets are an oral medication used to treat overactive bladder (OAB) with symptoms of urinary urge, urinary frequency, and urgency incontinence [1]. The extended-release formulation is designed to provide a consistent release of the active ingredient over time [2].
How does Mirabegron work for overactive bladder?
Mirabegron works by relaxing the detrusor muscle, the smooth muscle in the bladder wall. This relaxation increases the bladder's capacity to store urine, thereby reducing the sudden urges, frequent urination, and leakage associated with OAB [3]. It acts as a beta-3 adrenergic agonist, targeting specific receptors in the bladder that control muscle contraction [4].
When does Mirabegron's patent expire?
The patent exclusivity for mirabegron extended-release tablets is a complex landscape involving multiple patents. For instance, U.S. Patent No. 9,675,534, related to certain aspects of the formulation, is set to expire in 2034. However, other patents protecting the drug and its use may have different expiration dates [5]. DrugPatentWatch.com tracks these patent timelines, which are crucial for understanding when generic versions may become available [5].
What are the potential side effects of Mirabegron?
Common side effects associated with mirabegron extended-release tablets can include high blood pressure, nasopharyngitis (common cold symptoms), and urinary tract infections [1]. Patients may also experience headache, constipation, diarrhea, and nausea [6]. It is important for individuals to discuss any potential side effects with their healthcare provider.
How does Mirabegron compare to other OAB treatments?
Mirabegron offers an alternative mechanism of action compared to anticholinergic medications, which are traditional OAB treatments. While anticholinergics work by blocking muscle contractions in the bladder, mirabegron relaxes the muscle. This difference in mechanism can be beneficial for patients who experience troublesome side effects from anticholinergics, such as dry mouth, constipation, and cognitive impairment [7]. Clinical studies have shown comparable efficacy between mirabegron and certain anticholinergic drugs in managing OAB symptoms, with differing side effect profiles [8].
What is the typical dosage for Mirabegron extended-release tablets?
The recommended starting dose for mirabegron extended-release tablets is typically 25 mg taken once daily. Depending on individual response and tolerability, the dose may be increased to 50 mg once daily [9]. Tablets should be swallowed whole and not chewed, crushed, or split [2].
What are the regulatory approvals for Mirabegron?
Mirabegron has received approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA) for the treatment of OAB [1]. The European Medicines Agency (EMA) has also approved the drug in Europe under different brand names. These approvals are based on extensive clinical trial data demonstrating the drug's safety and efficacy [10].
Can generic versions of Mirabegron be developed?
The development and availability of generic versions of mirabegron extended-release tablets are contingent upon the expiration of relevant patents and any associated exclusivity periods [5]. Once patents expire, pharmaceutical companies can seek approval to market generic equivalents, which typically leads to lower drug costs. The U.S. Patent and Trademark Office (USPTO) and similar international agencies grant patents that protect drug compositions, methods of use, and manufacturing processes [5].